View Full Version : Lupin completes $880-mn Gavis purchase

03-10-2016, 12:08 PM
Pharmaceutical company Lupin has completed an $880-million acquisition of US generic drug maker Gavis, a deal announced last July.US business is 45 per cent of Lupinís revenue and the deal will enhance its product pipeline in dermatology, controlled substances and high-value specialty products. Gavis has 62 Abbreviated New Drug Applications (ANDAs) pending approval with the US Food and Drug Administration (FDA), beside 65 products under development. Lupin also gets access to Gavis' manufacturing facility in New Jersey, its first in that country.
Money Maker Research equity report (http://www.moneymakerfinancial.com/blog/daily-equity-report-by-money-maker-research/)